PMID- 23749906
OWN - NLM
STAT- MEDLINE
DCOM- 20130813
LR  - 20210223
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 33
IP  - 6
DP  - 2013 Jun
TI  - Cannabinoid receptor agonist as an alternative drug in 5-fluorouracil-resistant 
      gastric cancer cells.
PG  - 2541-7
AB  - Fluorouracil is the main chemotherapeutic drug used for gastrointestinal cancers, 
      which suffers the important problem of treatment resistance. There is little 
      information whether cannabinoid agonists can be used as an alternative drug for 
      fluorouracil-resistant gastric cancer cells. In this study, we investigated the 
      effects of a cannabinoid agonist, WIN-55,212-2, on 5-fluorouracil 
      (5-FU)-resistant human gastric cancer cells, to examine whether the cannabinoid 
      agonist may be an alternative therapy. Survival of the 5-FU-resistant gastric 
      cancer cell line, SNU-620-5FU/1000, was not significantly reduced even by a high 
      dose of 5-FU treatment. However, WIN-55,212-2 inhibited the proliferation of 
      SNU-620-5FU/1000 and enhanced their apoptosis, as indicated by an increase of 
      apoptotic cell proportion, activated caspase-3 and Poly (ADP-ribose) polymerase 
      cleavage. Furthermore, WIN-55,212-2 reduced 
      phospho-extracellular-signal-regulated kinases (ERK) 1/2, phospho-Akt (protein 
      kinase B), B-cell lymphoma-2 (BCL2) and BCL2-associated X (BAX) protein 
      expression in 5-FU-resistant gastric cancer cells. These results indicate that a 
      cannabinoid agonist may, indeed, be an alternative chemotherapeutic agent for 
      5-FU-resistant gastric cancer.
FAU - Xian, Xiang-Shu
AU  - Xian XS
AD  - Division of Gastroenterology, Department of Internal Medicine, College of 
      Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
FAU - Park, Hyeyeon
AU  - Park H
FAU - Choi, Myung-Gyu
AU  - Choi MG
FAU - Park, Jae Myung
AU  - Park JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzoxazines)
RN  - 0 (Cannabinoid Receptor Agonists)
RN  - 0 (Morpholines)
RN  - 0 (Naphthalenes)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Receptors, Cannabinoid)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 5H31GI9502 
      ((3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone)
RN  - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 3.4.22.- (Caspase 3)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Antimetabolites, Antineoplastic/pharmacology
MH  - Antineoplastic Agents/pharmacology
MH  - Apoptosis/drug effects
MH  - Benzoxazines/*pharmacology
MH  - Cannabinoid Receptor Agonists/*pharmacology
MH  - Caspase 3/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Drug Resistance, Neoplasm
MH  - Extracellular Signal-Regulated MAP Kinases/metabolism
MH  - Fluorouracil/pharmacology
MH  - Humans
MH  - Morpholines/*pharmacology
MH  - Naphthalenes/*pharmacology
MH  - Poly(ADP-ribose) Polymerases/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Proto-Oncogene Proteins c-bcl-2/metabolism
MH  - Receptors, Cannabinoid/*metabolism
MH  - Stomach Neoplasms/*drug therapy
MH  - bcl-2-Associated X Protein/metabolism
OTO - NOTNLM
OT  - Gastric cancer
OT  - apoptosis
OT  - cannabinoids
OT  - drug resistance
OT  - fluorouracil
EDAT- 2013/06/12 06:00
MHDA- 2013/08/14 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/06/11 06:00 [entrez]
PHST- 2013/06/12 06:00 [pubmed]
PHST- 2013/08/14 06:00 [medline]
AID - 33/6/2541 [pii]
PST - ppublish
SO  - Anticancer Res. 2013 Jun;33(6):2541-7.